July 11, 2014 11:48 PM ET


Company Overview of Dezima Pharma B.V.

Company Overview

Dezima Pharma B.V. develops novel compounds for treatment of cardiovascular disease related to dyslipidemia. The company is based in Naarden, the Netherlands.

Gooimeer 2-35

Naarden,  1411 DC



31 35 699 3000

Key Executives for Dezima Pharma B.V.

Chief Executive Officer
Founder and Chairman of Scientific Advisory Board
Age: 60
Compensation as of Fiscal Year 2014.

Dezima Pharma B.V. Key Developments

Dezima Pharma Completes Patient Enrolment for TULIP Phase 2B Study with CETP Inhibitor TA-8995

Dezima Pharma announced the completed enrolment of its phase 2b TULIP study. The aim of the study is to investigate the effects of TA-8995 (DEZ-001), a potential best-in-class CETP inhibitor, in around 360 patients with mild dyslipidemia on a wide range of plasma lipids, lipoproteins and validated biomarkers of cardiovascular disease (CVD). Recruitment for the double-blind, placebo-controlled, phase 2b dose ranging study of TA-8995 started in August 2013. The study has seen rapid enrolment in 17 specialized centres across the Netherlands and Denmark. The study has nine arms with patients receiving TA-8995 alone and in combination with statins. In addition, Dezima Pharma is currently preparing and executing a range of pre-clinical and clinical phase 3 enabling studies around its lead product, including a DDI study and a TQT study under an IND, in order to have a comprehensive partnering package.

Dezima Pharma Initiates Phase 2b TULIP Study on CETP Inhibitor Program DEZ-001

Dezima Pharma B.V. announced the initiation of a double blind, placebo controlled, Phase 2b dose ranging study of DEZ-001 (previously TA-8995), alone and in combination with statins, in order to study the effects on a wide range of lipids and other biomarkers of cardiovascular disease (CVD) in patients with mild dyslipidemia. The TULIP ("TA-8995: its Use in patients with mild dysLIPidemia") study will take place in specialized centres across Denmark and the Netherlands and will investigate the effects of different doses of DEZ-001 on established CVD biomarkers over a 3 month dosing period. DEZ-001 is a CETP inhibitor that has already demonstrated clinically relevant improvements on low-density lipoprotein (LDL) and high-density lipoprotein (HDL) levels as well as other lipid parameters in healthy volunteers.

Dezima Pharma Announces Executive Changes

Dezima Pharma announced that it has appointed Rob de Ree as its new Chief Executive Officer. Mr. de Ree has over 20 years of experience in sales & marketing, business development and general management in Pharma and Medtech, including Medtronic. Most recently he held the CEO position at Amsterdam-based cardiovascular monitoring company. Mr. de Ree is taking over from the company's interim CEO and General Partner of Forbion Capital Partners, Sander van Deventer, who has stepped down from the role, but will remain closely involved with the company by joining the Scientific Advisory Board.

Similar Private Companies By Industry

Company Name Region
Nycomed B.V. Europe
Ferring B.V. Europe
Therabel Pharma NV Europe
CyTuVax B.V. Europe
Biohorma BV Europe

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Bertelsmann AG Europe
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Dezima Pharma B.V., please visit www.dezimapharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.